UNSPSC 51293017: Protriptyline hydrochloride

This classification denotes a tricyclic antidepressant with the molecular formula C19H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44665V00O8, chemically known as 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene but more generally known as protriptyline hydrochloride, which bears US NIH Compound Identifier 4976. European Medicines Agency schedules Protriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04117MIG.

Most nations, for tariff and trade purposes, schedule protriptyline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, PROTRIPTYLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Protriptyline hydrochloride bears US NLM identifiers UMLS ID C0042910 and NCI Concept Code C47695. SMILES: CNCCCC1C2CCCCC2C=CC3C1CCCC3.CL.

UNSPSC 51293017 Protriptyline hydrochloride is a Commodity code that nominally names a specific antidepressant medication, but recent state and local procurement activity under this code actually encompasses broader pharmaceutical procurement — generic multi-source pharmaceuticals, over-the-counter products, and emergency response medications such as naloxone. State and local governments soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, recently issued IFB 60459723LAS to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries and a two-year initial contract term plus one-year renewal option. The Texas Health and Human Services Commission posted an exploratory Request for Information (RFI HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative pharmaceutical supply chain arrangements.

Geographic activity appears concentrated in the South and Midwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions, with proposals due March 26, 2026. MMCAP's RFP requires vendors to supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with contract effectiveness July 1, 2026, and emphasizes price competitiveness (weighted at 75 percent) alongside cGMP and Drug Supply Chain Security Act compliance. The code shows modest but active recent procurement, with mixed issuing bodies (county health departments, state health agencies, and cooperative purchasing vehicles) and no disclosed dollar values across the opportunities identified.